News Releases Keyword Search Year None20202019201820172016 Feb-22-2017 Oncternal Closes $18.4 Million Series B Financing Dec-06-2016 Oncternal’s Pipeline Candidates Featured in Presentations at American Society of Hematology Meeting Aug-30-2016 Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma Jul-13-2016 TK216 Receives Orphan Drug Designation for the Treatment of Ewing Sarcoma, a Rare Pediatric Cancer Jun-20-2016 Oncternal Receives Fast Track Designation for TK216 in Relapsed or Refractory Ewing Sarcoma Jun-01-2016 Oncternal Merges with Tokalas to Form Clinical-Stage Biotech Company w/ Promising Oncology Pipeline Apr-12-2016 Oncternal Awarded Exclusive Worldwide License to ROR1 Antibody and Related Programs from UCSD Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5
